Table 1 Samples obtained from a commercial brain
From: R-RAS2 overexpression in tumors of the human central nervous system
Histo-Pathology | Grade1 | Patients | Samples | Mean age | Men (%) |
|---|---|---|---|---|---|
a) Clinicopathologic data of 193 human CNS samples | |||||
Brain tissue | - | 13 | 23 | 35,3 ± 19,2 | 38,5 |
Hyperplasia | - | 2 | 3 | 34,7 ± 8,1 | 50 |
Mixed glioma | - | 2 | 4 | 41 ± 3,5 | 100 |
Glioblastoma | III | 7 | 13 | 60,5 ± 14,4 | 85,7 |
IV | 9 | 15 | 49,5 ± 16,9 | 66,6 | |
Astrocytoma | I | 32 | 59 | 37,6 ± 10,3 | 69,6 |
II | 28 | 54 | 43,5 ± 14,2 | 60,7 | |
III | 5 | 9 | 44,4 ± 7,3 | 20 | |
Oligodendroglioma | I-II | 2 | 4 | 29,5 ± 0,6 | 50 |
II-III | 3 | 5 | 57,4 ± 15,1 | 100 | |
III | 2 | 4 | 42,5 ± 11 | 100 | |
b) Clinicopathologic data of 56 human CNS tumor samples | |||||
Medulloblastoma | IV | 6 | 18 | 8,8 ± 5 | 66,6 |
Cerebroma | IV | 3 | 9 | 26,6 ± 16,9 | 33,3 |
Meningioma | IV | 4 | 11 | 40 ± 9,5 | 75 |
Ependymoma | IV | 1 | 3 | 14 ± 0 | 100 |
Undifferenciated | IV | 5 | 15 | 11,2 ± 4 | 60 |
Histo-Pathology | Grade 1 | Patients | Mean age | Men (%) | |
c) Clinicopathologic data of 32 human CNS samples | |||||
Brain tissue | - | 1 | 55 | 0 | |
Hyperplasia | - | 1 | 45 ± 0 | 100 | |
Astrocytoma | I | 1 | 27 ± 0 | 0 | |
II | 2 | 39,5 ± 19,1 | 50 | ||
III | 3 | 35 ± 4,6 | 100 | ||
Oligoastrocytoma | II | 1 | 37 ± 0 | 0 | |
III | 1 | 41 ± 0 | 100 | ||
Oligodendroglioma | II | 1 | 33 ± 0 | 100 | |
III | 3 | 45,3 ± 5,1 | 0 | ||
Ependymoma | III | 1 | 49 ±0 | 0 | |
Meningioma | I | 13 | 53,8 ± 13,6 | 38,5 | |
II | 4 | 61 ± 11,2 | 50 | ||